The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Economic burden of advanced hepatocellular carcinoma (HCC) in Spain among patients discontinuing first-line sorafenib.
Astra M. Liepa
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Sean D. Candrilli
Consultant or Advisory Role - Lilly
Yulia D'yachkova
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Kaisa Taipale
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
James A. Kaye
Consultant or Advisory Role - Lilly